Johnson & Johnson shares catch Jim Cramer’s attention as he cites pipeline strength and a valuation reset from spin-offs

Jim Cramer has continued to single out Johnson & Johnson as one of the standout performers in 2026, using the healthcare giant as an example of how established drug makers can still deliver results while investors rotate away from parts of the tech-led market. In coverage referenced by Yahoo Finance, Cramer placed Johnson & Johnson (NYSE: JNJ) among the “biggest winners” he has highlighted this year.

The commentary also ties J&J’s stock performance to specific operational and financial milestones. According to an article that summarizes Cramer’s framing, Johnson & Johnson’s shares were up 68% over the prior 12 months and up 26% year-to-date at the time of publication. The same piece points to J&J’s fourth-quarter results reported on January 21, citing $24.56 billion in revenue and $2.46 in earnings per share, which it says beat analyst estimates.

Cramer’s thesis, as quoted in the write-up, leaned on business mix changes he argues could change how the market values the company. He cited the separation of J&J’s orthopedics business, DePuy Synthes, saying the move “will immediately raise its price-to-earnings multiple because that business has much slower growth than the core pharma franchise.” Cramer also referenced the earlier spinoff of Kenvue, J&J’s consumer health business, as a comparable valuation step-up event.

In the same summary, J&J’s full-year outlook is presented as part of the case for durability. The article states that the company guided full-year revenue to a range of $99.5 billion to $100.5 billion, and forecast profit per share of $11.43 to $11.63, both described as above analyst expectations. It frames those targets as supporting evidence behind Cramer’s growing optimism over the past year.

Beyond separations, the write-up emphasizes pipeline strength, particularly oncology. It says Cramer’s attention has been drawn to J&J’s “robust oncology portfolio” as part of what he sees as a growth engine inside the core pharmaceutical business.

Separately, CNBC commentary earlier this year suggested Cramer was looking for “antidotes” outside the AI and momentum-heavy areas of the market if technology began to show fatigue. In that framing, he pointed to J&J alongside other non-tech names as diversification candidates if the market cools. That broader stance provides context for why an older, cash-generating healthcare company remains on his watch list.

Even with the bullish framing, the market angle here is mostly about narrative and valuation expectations rather than new, company-filed disclosures. The details of Cramer’s claims and the stock-performance figures appear in third-party coverage summarizing his remarks, while the Yahoo Finance headline itself directs readers to that commentary. J&J’s own investor materials for the quarter and guidance are not reproduced in the post, so readers looking for confirmation would need to cross-check with J&J’s earnings release and filings.

Going forward, investors will likely watch whether J&J’s operational execution holds up as management reshapes the portfolio through business separations, and whether guidance continues to track the company’s stated ranges. The key question for the market, in Cramer’s telling, is whether separating slower-growth units leaves investors willing to pay a higher multiple for the remaining “core pharma” business. Next updates that could clarify that trajectory include continued quarterly results and any additional guidance or timelines related to the separations process.